Publications

03-29 05:42
 
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
03-29 05:42
 
Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis
03-29 05:41
 
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
03-29 05:41
 
Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR cohort of Indian patients with multibacillary leprosy
03-29 05:41
 
Classification of leprosy into multibacillary and paucibacillary groups: an analysis
03-29 05:41
 
Measurement of cardiac index by transpulmonary thermodilution using an implanted central venous access port: a prospective study in patients scheduled for oncologic high-risk surgery
03-29 05:41
 
Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients
03-29 05:41
 
Mindfulness meditation training to reduce symptom distress in transplant patients: rationale, design, and experience with a recycled waitlist
03-29 05:41
 
Mindfulness-based stress reduction for solid organ transplant recipients: a randomized controlled trial
03-29 05:41
 
Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human
03-29 05:41
 
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults
03-29 05:41
 
Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection
03-29 05:41
 
Effect of topical treatment with 7.5% urea in Ichthyosis Vulgaris: A randomized, controlled, double blinded, split body study evaluating the effect of urea cream compared to the vehicle (moisturizing) cream
03-29 05:41
 
Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study
03-29 05:41
 
Tuberculosis control in resource-poor countries: have we reached the limits of the universal paradigm?
03-29 05:41
 
A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
03-29 05:41
 
Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4
03-29 05:41
 
52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
03-29 05:41
 
Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
03-29 05:41
 
Gait speed and pedestrian crossings in COPD
03-29 05:41
 
Blood pressure levels in male carriers of Arg82Cys in CD300LG
03-29 05:41
 
Reduced CD300LG mRNA tissue expression, increased intramyocellular lipid content and impaired glucose metabolism in healthy male carriers of Arg82Cys in CD300LG: a novel genometabolic cross-link between CD300LG and common metabolic phenotypes
03-29 05:41
 
Impact of pharmacy care upon adherence to cardiovascular medicines: a feasibility pilot controlled trial
03-29 05:41
 
Exploring patients' reasons for discontinuance of heart medications
03-29 05:41
 
Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT)

Clinical Research News

Applying for a Paediatric investigation plan (PIP): review of the EMA guidelines
Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults

Aankomende klinische onderzoeken

Clinical Research Jobs

All jobs

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren